Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/VT-464> ?p ?o }
Showing triples 1 to 99 of
99
with 100 triples per page.
- VT-464 abstract "VT-464 is an experimental cancer treatment for a type of prostate cancer. It is being developed by Viamet Pharmaceuticals.It is a non-steroidal antiandrogen, acting specifically as an androgen synthesis inhibitor via inhibition of the enzyme CYP17A1, for the treatment of castration-resistant prostate cancer. It has approximately 10-fold selectivity for the inhibition of 17,20-lyase (IC50 = 69 nM) over 17α-hydroxylase (IC50 = 670 nM), which results in less interference with corticosteroid production relative to the approved CYP17A1 inhibitor abiraterone acetate (which must be administered in combination with prednisone to avoid glucocorticoid deficiency and mineralocorticoid excess due to 17α-hydroxylase inhibition) and hence may be administerable without a concomitant exogenous glucocorticoid. VT-464 is 58-fold more selective for inhibition of 17,20-lyase than abiraterone, which has IC50 values for inhibition of 17,20-lyase and 17α-hydroxylase of 15 nM and 2.5 nM, respectively. In addition, in in vitro models, VT-464 appears to possess greater efficacy as an antiandrogen relative to abiraterone. Similarly to abiraterone acetate, VT-464 has also been found to act to some extent as an antagonist of the androgen receptor.As of June 2014, VT-464 has reached phase II clinical trials for prostate cancer.".
- VT-464 atcPrefix "None".
- VT-464 casNumber "1610537-15-9".
- VT-464 fdaUniiCode "8S5OIN36X4".
- VT-464 iupacName "(1S)-1-[6,7-Bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(2H-triazol-4-yl)propan-1-ol".
- VT-464 pubchem "78357816".
- VT-464 thumbnail VT-464.svg?width=300.
- VT-464 wikiPageExternalLink 800035241.
- VT-464 wikiPageID "47288627".
- VT-464 wikiPageLength "6564".
- VT-464 wikiPageOutDegree "43".
- VT-464 wikiPageRevisionID "690612429".
- VT-464 wikiPageWikiLink Abiraterone_acetate.
- VT-464 wikiPageWikiLink Adrenal_insufficiency.
- VT-464 wikiPageWikiLink Androgen.
- VT-464 wikiPageWikiLink Androgen_receptor.
- VT-464 wikiPageWikiLink Antiandrogen.
- VT-464 wikiPageWikiLink Apalutamide.
- VT-464 wikiPageWikiLink Biosynthesis.
- VT-464 wikiPageWikiLink CYP17A1.
- VT-464 wikiPageWikiLink Category:Alcohols.
- VT-464 wikiPageWikiLink Category:Antiandrogens.
- VT-464 wikiPageWikiLink Category:Enzyme_inhibitors.
- VT-464 wikiPageWikiLink Category:Experimental_cancer_drugs.
- VT-464 wikiPageWikiLink Category:Naphthalenes.
- VT-464 wikiPageWikiLink Category:Organofluorides.
- VT-464 wikiPageWikiLink Category:Prostate_cancer.
- VT-464 wikiPageWikiLink Category:Triazoles.
- VT-464 wikiPageWikiLink Clinical_trial.
- VT-464 wikiPageWikiLink Corticosteroid.
- VT-464 wikiPageWikiLink Cyproterone_acetate.
- VT-464 wikiPageWikiLink EPI-001.
- VT-464 wikiPageWikiLink Enzalutamide.
- VT-464 wikiPageWikiLink Enzyme.
- VT-464 wikiPageWikiLink Enzyme_inhibitor.
- VT-464 wikiPageWikiLink Exogeny.
- VT-464 wikiPageWikiLink Experimental_cancer_treatment.
- VT-464 wikiPageWikiLink Galeterone.
- VT-464 wikiPageWikiLink Glucocorticoid.
- VT-464 wikiPageWikiLink Hyperaldosteronism.
- VT-464 wikiPageWikiLink IC50.
- VT-464 wikiPageWikiLink In_vitro.
- VT-464 wikiPageWikiLink Mouth.
- VT-464 wikiPageWikiLink Nonsteroidal.
- VT-464 wikiPageWikiLink ODM-201.
- VT-464 wikiPageWikiLink Orteronel.
- VT-464 wikiPageWikiLink Phases_of_clinical_research.
- VT-464 wikiPageWikiLink Prednisone.
- VT-464 wikiPageWikiLink Prostate_cancer.
- VT-464 wikiPageWikiLink Receptor_antagonist.
- VT-464 wikiPageWikiLink Viamet_Pharmaceuticals.
- VT-464 wikiPageWikiLinkText "VT-464".
- VT-464 atcPrefix "None".
- VT-464 c "18".
- VT-464 casNumber "1610537".
- VT-464 chemspiderid "32738723".
- VT-464 f "4".
- VT-464 h "17".
- VT-464 inchi "InChI=1S/C18H17F4N3O3/c1-91812-4-3-10-6-13147-115-12/h3-9,16-17,26H,1-2H3,/t18-/m0/s1".
- VT-464 inchikey "ZBRAJOQFSNYJMF-SFHVURJKSA-N".
- VT-464 iupacName "-1".
- VT-464 molecularWeight "399.339493".
- VT-464 n "3".
- VT-464 o "3".
- VT-464 pubchem "78357816".
- VT-464 routesOfAdministration Mouth.
- VT-464 smiles "CCCO".
- VT-464 unii "8".
- VT-464 width "200".
- VT-464 wikiPageUsesTemplate Template:Androgenics.
- VT-464 wikiPageUsesTemplate Template:Antiandrogens.
- VT-464 wikiPageUsesTemplate Template:Cite_journal.
- VT-464 wikiPageUsesTemplate Template:Drug-stub.
- VT-464 wikiPageUsesTemplate Template:Drugbox.
- VT-464 wikiPageUsesTemplate Template:Fdacite.
- VT-464 wikiPageUsesTemplate Template:NOTOC.
- VT-464 wikiPageUsesTemplate Template:Reflist.
- VT-464 wikiPageUsesTemplate Template:Steroid_hormone_metabolism_modulators.
- VT-464 subject Category:Alcohols.
- VT-464 subject Category:Antiandrogens.
- VT-464 subject Category:Enzyme_inhibitors.
- VT-464 subject Category:Experimental_cancer_drugs.
- VT-464 subject Category:Naphthalenes.
- VT-464 subject Category:Organofluorides.
- VT-464 subject Category:Prostate_cancer.
- VT-464 subject Category:Triazoles.
- VT-464 hypernym Treatment.
- VT-464 type ChemicalSubstance.
- VT-464 type Drug.
- VT-464 type ChemicalObject.
- VT-464 type Thing.
- VT-464 type Q8386.
- VT-464 comment "VT-464 is an experimental cancer treatment for a type of prostate cancer. It is being developed by Viamet Pharmaceuticals.It is a non-steroidal antiandrogen, acting specifically as an androgen synthesis inhibitor via inhibition of the enzyme CYP17A1, for the treatment of castration-resistant prostate cancer.".
- VT-464 label "VT-464".
- VT-464 sameAs Q21098941.
- VT-464 sameAs Q21098941.
- VT-464 wasDerivedFrom VT-464?oldid=690612429.
- VT-464 depiction VT-464.svg.
- VT-464 isPrimaryTopicOf VT-464.